Novel sustained release formulation of IFN alpha -2b improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial

Saved in:
Bibliographic Details
Published inJournal of clinical virology Vol. 36; p. S24
Main Authors Trepo, C, Meyrueix, R, Maynard, M, Rouzier, R, Bourliere, M, Donazzolo, Y, Zarski, J, Kravtzoff, R
Format Journal Article
LanguageEnglish
Published 01.01.2006
Subjects
Hepatitis C virus
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-1
ISSN:1386-6532